These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 30684076)

  • 1. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Cheung KS; Ng HY; Hui RWH; Lam LK; Mak LY; Ho YC; Tan JT; Chan EW; Seto WK; Yuen MF; Leung WK
    Hepatology; 2024 Oct; 80(4):916-927. PubMed ID: 38536017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
    Babar M; Hussain M; Ahmad M; Akhtar L
    J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.
    Bilgin S; Kurtkulagi O; Duman TT; Tel BMA; Kahveci G; Kiran M; Erge E; Aktas G
    Ir J Med Sci; 2022 Aug; 191(4):1647-1652. PubMed ID: 34476725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.